MedTrace Logo

Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

NCT02708173 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-08-15

No results posted yet for this study

Summary

This study evaluates the safety of Quadrivalent Influenza Virus Vaccine in Healthy People Aged years 3 to 60.40 Subjects will be equally divided into 2 groups,including 3-17 years old and 18-60 years old.Adult group first receive one dose of Quadrivalent Influenza Virus Vaccine.Then minors group also receive one dose of Quadrivalent Influenza Virus Vaccine after 7 days.

Conditions

  • Quadrivalent Influenza Virus Vaccine

Interventions

BIOLOGICAL

One dose of Quadrivalent Influenza Virus Vaccine

BIOLOGICAL

One dose of Quadrivalent Influenza Virus Vaccine

Sponsors & Collaborators

  • Beijing Chaoyang District Centre for Disease Control and Prevention

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-03-31
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02708173 on ClinicalTrials.gov